Semaglutide for Major Depressive Disorder

Written By Hartej Gill

This is a 16-week, placebo-controlled, randomized, double-blind, clinical trial, involving 60 overweight individuals with MDD and pre-treatment cognitive dysfunction. Study participants will receive one of the following study interventions in addition to 'standard of care' treatment:

once-daily semaglutide, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks; or matching placebo. Participants will be assessed to examine the effect of semaglutide on their cognitive function.

You may be eligible if:

  • Age 18-60yrs.

  • Body Mass Index ≥25 kg/m2

  • Diagnosed with Major depressive Disorder

More information can be found at: https://clinicaltrials.gov/ct2/show/NCT04466345

Hartej Gill
Next

Anhedonia and the Insulin Pathway